Navigation Links
Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
Date:2/14/2008

NATICK, Mass., Feb. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Fluid Management and Venous Access businesses to Avista Capital Partners for $425 million in cash. The sale follows the definitive agreement announced on December 13, 2007.

The Company expects to record an after-tax gain of approximately $120 million during the first quarter of 2008 in connection with the transaction.

"The sale of the Fluid Management and Venous Access businesses completes our previously announced plans to divest five non-strategic businesses," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These divestitures -- together with our expense and head count reductions and business restructuring -- are helping to realign our cost structure and simplify our operating model. The positive impact of these efforts will help us achieve our overall goals of restoring profitable growth, increasing shareholder value and strengthening Boston Scientific for the future."

"I am very excited to work with this exceptional management team to build on the strong leadership positions that the Fluid Management and Venous Access businesses currently hold in the cardiology, radiology and oncology markets," said Ron Sparks, Chairman and Chief Executive Officer of the new company. "We look forward to leveraging these franchises' brands, manufacturing facilities, sales forces, R&D capabilities and new product pipelines to create a world- class, stand-alone medical device company."

Avista said financing for the transaction was arranged by GE Capital Corporation and RBS Greenwich Capital. Ropes & Gray LLP served as legal counsel and RBS Greenwich Capital
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...cies offering CareOne Credit Counseling Services (...n of free tips and advice on how consumers can sta...ng out. , Baltimore, MD (...,s resolutions early this year? By focusing on fit...ff cold weather weight gain, but become more finan...
(Date:10/7/2008)...strial Specialties, Mfg. is pleased to announce th... These filters are exclusively available from Indu...st push-to-connect style fittings integrated into ...line filter offers versatility and customization f... (PRWEB) October 7, 2008 -- Exclusively avai...
(Date:10/7/2008)...re-FirstCall/ -- Bull - expert in open,flexible a...ces and one of,Europe,s leading players in the IT ...reement for the acquisition of its Medicaid soluti...d Human Services management,in the United States b...y,and consulting services company. These operation...
(Date:10/6/2008)...oney, since side effects can affect length of stay...hDay News) -- Simple changes to hospital procedure...en suffer while on opiates to relieve pain, a new ...ration between 14 U.S. children,s hospitals, docum...used by the pain relievers under these new procedu...
Breaking Medicine News(10 mins):Health News:Credit Counseling Agency Helps Consumers Live Healthier While Becoming Financially Fit 2Health News:Credit Counseling Agency Helps Consumers Live Healthier While Becoming Financially Fit 3Health News:Bull Continues Repositioning and Announces the Acquisition of its Medicaid Solutions Business in the United States by Ingenix 2Health News:Bull Continues Repositioning and Announces the Acquisition of its Medicaid Solutions Business in the United States by Ingenix 3Health News:Hospital Fixes Cut Opiate Errors in Kids 2
...form gene mapping, ten times faster than the conve...omputers// and unwind the mysteries associated wit...ducted by researchers from Technion-Israel Institu... the American Journal of Human Genetics, June 2006...
...as included the name of a Class 10 correspondence ...it had earlier failed to do, an official said Satu...ate had named 22 students of various private and g...ts list of toppers last Wednesday. But Pravas Ku...
... are particularly essential for proper embryo deve... can lead to birth defects such as cleft palate, s...a collaborative effort of the University of Colora...ward Hughes Medical Research Institute. The findi...
..., which follows after eating (traditionally called... as a physiologic happening due to changes in gluc...d body activity in humans and as well as in animal...thus we are in need of a small nap - researchers a...
Other Medicine News:Health News:Sleeping Computers Yield Clues About Genetic Disorders 2
(Date:10/6/2008)...or to the understanding of and possible t..., BILLERICA, Mass., Oct. 6 /- Seahor...irst ever analytical instrument for the,kinetic me...cytoplasmic,glycolysis in cells in a 96 well micro...ellular bioenergetics have been relatively unchang...
(Date:10/6/2008)...s with Durezol Dosed Prior to Surgery, TAMPA, Fla...., a,privately held ophthalmic-focused biopharmace...difluprednate ophthalmic emulsion) 0.05% is now,co...by the U.S. Food and,Drug Administration in June 2...ted for the treatment of inflammation and pain ass...
(Date:10/6/2008)...heduled for 9:00 AM ET Today -, SEATTLE, Oct. 6 /...daq:,DNDN) announced today that it has completed t...ized, double-blind, placebo-controlled IMPACT,(IMm...also known as D9902B),clinical trial designed to a...al active cellular immunotherapy PROVENGE(R) (sipu...
(Date:10/6/2008)...inking polyphenol-rich 100% Concord grape,juice wa...intake or body,weight, CONCORD, Mass., Oct. 6 /PR...l-rich Concord grape juice did not cause significa... appetite and was shown to reduce waist,circumfere...nual Meeting of,the American College of Nutrition ...
Breaking Medicine Technology:Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA 1943 1China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA 1943 2China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA 1943 3China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA 1943 4Signalife Receives FDA Clearance for OTC Non Prescription Event Recorder Device 1941 1Signalife Receives FDA Clearance for OTC Non Prescription Event Recorder Device 1941 2Signalife Receives FDA Clearance for OTC Non Prescription Event Recorder Device 1941 3Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference 1939 1Bio advancements Expected to Drive Burn Care Market Growth Up 24700 Million 1937 1Bio advancements Expected to Drive Burn Care Market Growth Up 24700 Million 1937 2
...IRE) -- July 02, 2007 -- DOR BioPharma, Inc.,(OTCB...that the,first results from testing of a multivale...ade;, have been published in the journal,Infection...n and,Immunity, v. 75, p. 3043 ). These results ar...elicited by a multivalent vaccine,that is active b...
...o Timeline for Second Pivotal Phase 3 Trial CL-05,...Advanced Life,Sciences Holdings, Inc. , today anno...ta from Trial CL-06, the first of two,pivotal Phas...and,effectiveness of cethromycin, a novel once-a-d...ired pneumonia (CAP). The Company,also provided an...
Other Medicine Technology:DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7
New Image Drainable Pouch, Ultra-Clear without Filter
New Image Drainable Mini-Pouch, Beige
New Image Cut-to-Fit Flextend Skin Barrier, Floating Flange, with Tape
New Image Cut-to-Fit Convex Flextend Skin Barrier, with Tape
Medicine Products: